Maravai LifeSciences (MRVI) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

MRVI · Stock Price

USD 3.94+1.87 (+90.34%)

Market Cap: $581.1M

Historical price data

Market Cap: $581.1MFounded: 2014Employees: 1000-5000HQ: San Diego, United States

Sector Ranking#5 in mRNA Therapeutics #23 in Cell & Gene Therapy

Overview

Maravai LifeSciences operates as a mission-critical infrastructure provider for the global life sciences industry, with a focus on nucleic acid synthesis and biologics safety testing. The company gained significant prominence during the COVID-19 pandemic as its CleanCap® technology became a key component in leading mRNA vaccines. Its strategy is to leverage its proprietary technology platforms and deep expertise to support the expanding pipeline of genetic medicines and biologics, positioning itself as an essential partner for innovation.

Infectious DiseasesOncologyCardiologyNeurological Disorders

Technology Platform

Maravai's platform consists of proprietary technologies for nucleic acid synthesis, including the industry-leading CleanCap® mRNA capping technology and a broad portfolio of modified nucleotides, coupled with best-in-class biologics safety testing assays for impurity detection.

Funding History

3

Total raised:$2.0B

IPO$1.7BUndisclosedNov 20, 2020

Debt$200MGoldman SachsDec 15, 2019

Series A$50MGTCRSep 15, 2015

Opportunities

The primary opportunity lies in the expansion of mRNA therapeutics into new disease areas like oncology and rare diseases, creating a long-term, growing demand for Maravai's nucleotides and capping technology.

Additionally, the increasing complexity of biologic drugs and stringent regulatory requirements drive recurring revenue for its essential safety testing services.

Risk Factors

Key risks include the sharp normalization of post-pandemic revenue, dependence on the success and adoption rate of customer mRNA pipelines beyond COVID-19, and potential technological disruption in the rapidly evolving nucleic acid therapy space.

Competitive Landscape

Maravai competes with large, diversified life science tools companies (e.g., Thermo Fisher, Merck KGaA) and specialized assay providers. Its competitive edge is its proprietary, best-in-class technologies like CleanCap® and F550® assays, deep technical expertise, and integrated service model across the drug development lifecycle.